Contracts › 75N91020F00005
75N91020F00005: Evaluation of Two Different Classes of Compounds (STAT3 Inhibitors and Serms) for the Prevention of Urinary Bladder Cancer.
Awarded to University of Oklahoma by National Institutes of Health (NIH).
$910Kobligated
$910Kpotential value
01 November 2026current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75N91020F00005 |
|---|---|
| Vehicle | 75N91019D00020 |
| Awardee | University of Oklahoma |
| Awarding agency | National Institutes of Health (NIH) |
| Awarding office | NIH NCI |
| NAICS | 541714 Research and Development in Biotechnology (Except Nanobiotechnology) |
| PSC | AN91 R&D- Medical: Other (Basic Research) |
| Place of performance | OK |
| Offers received | 1 |
| Period of performance | 21 September 2020 to 01 November 2026 |
| Potential end | 01 November 2026 |
| Estimated recompete solicitation | Now / imminent (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 04 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541714 contracts · All expiring contracts · USASpending record